Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ipatasertib is an orally bioavailable, small-molecule pan-AKT inhibitor that targets all three isoforms of the AKT protein (AKT1, AKT2, and AKT3). By inhibiting AKT, it blocks the PI3K/AKT/mTOR signaling pathway, which is frequently hyperactivated in various cancers and contributes to tumor cell growth, survival, and resistance to therapy. Developed through a partnership between Genentech and Array BioPharma (later acquired by Pfizer), ipatasertib was extensively investigated in Phase III clinical trials for metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC). However, Roche discontinued its development in 2022 following the drug's failure to meet primary efficacy endpoints in key late-stage trials.
- Other names
- 艾帕洛利
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)
Beyond the preview
Go deeper on ipatasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib.